Lehigh Valley Health Network LVHN Scholarly Works

Research Scholars Poster Presentation

Outcomes of Patients on Extracorporeal Membrane Oxygenation (ECMO) for Periods of Time without Anticoagulation at LVHN in the Past 3 Years

Bryan Auvil

Rosalie Mattiola

Rita Pechulis MD, FCCP Lehigh Valley Health Network, Rita_M.Pechulis@lvhn.org

James Wu MD Lehigh Valley Health Network, james.wu@lvhn.org

Biren Juthani DO Lehigh Valley Health Network, Biren.Juthani@lvhn.org

Follow this and additional works at: https://scholarlyworks.lvhn.org/research-scholars-posters Let us know how access to this document benefits you

Published In/Presented At

Auvil, B., Mattiola, R., Pechulis, R., Wu, J. (2015, July 31). *Outcomes of Patients on Extracorporeal Membrane Oxygenation (ECMO) for Periods of Time Without Anticoagulation at LVHN in the Past 3 Years.* Poster presented at LVHN Research Scholar Program Poster Session, Lehigh Valley Health Network, Allentown, PA.

Juthani, B. (2015, September 18). *Outcomes of Patients on Extracorporeal Membrane Oxygenation (ECMO) for Periods of Time Without Anticoagulation at LVHN in the Past 3 Years.* Poster presented at the 26th Annual Extracorporeal Life Support Organization Conference, Atlanta, GA.

This Poster is brought to you for free and open access by LVHN Scholarly Works. It has been accepted for inclusion in LVHN Scholarly Works by an authorized administrator. For more information, please contact LibraryServices@lvhn.org.

Outcomes of Patients on Extracorporeal Membrane Oxygenation (ECMO) for Periods of Time Without Anticoagulation at LVHN in the Past 3 Years Bryan Auvil, Rosalie Mattiola, Biren Juthani DO, Rita Pechulis, MD, James Wu, MD Department of Surgery, Division of Cardiothoracic Surgery, Lehigh Valley Health Network, Allentown, Pennsylvania

Background

Extracorporeal membrane oxygenation (ECMO) is an aggressive life support technique that utilizes extracorporeal circuits and oxygenators to support severe lung injury such as acute respiratory distress syndrome (ARDS), as well as severe cardiac disorders like cardiogenic shock and cardiac arrest. Veno-Venous (VV) ECMO is primarily used in respiratory distress.¹ Clots can form within the oxygenator or circuit, and can be pushed into the patient, ultimately causing a thrombus, or in severe cases, a stroke. To prevent this, patients undergo anticoagulation (AC) therapy and are uniformly heparinized. However patients can develop bleeding complications, and therefore must have their AC discontinued. There is no significant body of literature regarding safety and outcome of patients on ECMO in whom anticoagulation is held secondary to bleeding complications.

Methods

A retrospective study was done involving 57 patients in 2013-2015 within the Lehigh Valley Health Network that were on VV ECMO. Data was examined for each patient from electronic medial records. Outcomes of patients whose anticoagulation was held for at least one period over 24 hours (Group A) were compared to those of patients whose anticoagulation was not held (Group B). The overall exclusion criteria were being less than 18 years old or not having been on VV ECMO within LVHN since 2013.

Table 1. LVHN VV ECMO Data 2013-2015		
	Group A	Group B
Total # of patients	19	38
Gender (% male)	47% (9/19)	42% (16/38)
Average age	46	49
Average time on ECMO (days)	25	10
Median time on ECMO (days)	21	7
Average time heparin held (hr)	175	N/A
Median time heparin held (hr)	113	N/A
Oxygenator/circuit changes	58% (11/19)	7.8% (3/38)
Rate of oxygenator/circuit changes (total #/days on ECMO)	0.034 (16/475 days)	0.0079 (3/379)
LE DVT	26% (5/19)	13% (5/38)
Rate of LE DVT (#/days on ECMO)	0.017 (8/475 days)	0.013 (5/379 days)
UE DVT	26% (5/19)	11% (4/38)
Rate of UE DVT (#/days on ECMO)	0.017 (8/475 days)	0.026 (10/379 days)
Mortalitay	47% (9/19)	29% (11/38)
Family withdrew care	67% (6/9)	64% (7/11)
Discharged to home	11% (2/19)	18% (7/38)
Discharged to rehab facility	42% (8/19)	55% (21/38)

Group A – heparin held >24 hrs. Group B – Control. LE: Lower extremity. UE: Upper extremity. DVT: Deep Venous Thrombosis.




Figure 1. Patient Outcomes

Results




Table 2. Causes of Death for Heparin-held Patients

Pt #	Cause	Outcome
1	Bleeding	Family w/d care
2	Sepsis	Family w/d care
3	Shock/ cardiac arrest	Family w/d care
4	Air embolism and hypoxia leading to brain death	Death
5	Sepsis	Family w/d care
6	Prolonged ECMO w/o improvement	Family w/d care
7	Prolonged ECMO w/o improvement	Family w/d care
8	Bleeding	Death
9	Brain edema and herniation	Death




Figure 3. Timing of Oxygenator/circuit

While Heparin on Hold

While on Heparin

Conclusions

Patients whose heparin was held for period(s) of at least 24 hours required oxygenator and circuit changes much more frequently. They also experienced more DVTs and had a higher mortality rate; however, their overall rate of DVTs per day on ECMO is similar that of the control group, indicating that the increased incidence of DVT is likely due to the significantly longer average amount of time those patients spent on ECMO relative to control patients. Patients in the non-heparinized cohort mostly died when the families withdrew care because of prolonged ECMO without improvement, worsening sepsis, and/or severe bleeding complications. Based on these findings there is no direct evidence that temporarily discontinuing AC resulted in increased patient mortality. This was more likely due to increased severity of illness and bleeding complications, requiring more time on ECMO.

References:

1. D Brodie, M Bacchetta. Extracorporeal Membrane Oxygenation for ARDS in Adults. *N Engl J Med* 2011;365:1905-14.

© 2015 Lehigh Valley Health Network

A PASSION FOR BETTER MEDICINE."

610-402-CARE LVHN.org

